Telling the truth about chemo may improve End-of-Life care

NCT ID NCT02606149

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether explaining the risks of chemotherapy more honestly to patients with incurable lung cancer could reduce the number who receive chemo in their last month of life. Researchers randomly assigned 123 patients to either standard information or a more detailed talk about how chemo might worsen life-threatening conditions. The goal was to see if better communication leads to less aggressive care and more focus on comfort and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that honest communication about chemotherapy risks helps patients avoid unnecessary treatment and improves end-of-life care quality.
What could go wrong: This is a small, single-center study testing a communication strategy, not a drug. Results may not apply broadly, and the intervention may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAGE IV LUNG CANCER

Contacts and locations

Locations

Hôpital Cochin

Paris, Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.